Point72 Asset Management’s BioAtla BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-12,994
Closed -$5.36M 2234
2022
Q4
$5.36M Sell
12,994
-2,300
-15% -$954K 0.02% 731
2022
Q3
$5.89M Buy
+15,294
New +$5.01M 0.02% 664
2021
Q4
Sell
-2,572
Closed -$3.79M 1088
2021
Q3
$3.79M Buy
+2,572
New +$5.01M 0.02% 714

Other funds holding BCAB

Point72 Asset Management's BCAB Position: Q1 2023 in Review

Point72 Asset Management sold out of BioAtla (BCAB) in Q1 2023, closing a stake of 12,994 shares — an estimated $5.36M sold.

Point72 Asset Management first reported a position in BCAB in Q3 2021 and held it in 3 quarters. The position peaked at $5.89M in Q3 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q1 2023.

  • Point72 Asset Management reported no remaining BioAtla position as of Q1 2023 after selling out during the quarter.
  • Point72 Asset Management sold 12,994 BioAtla shares in Q1 2023, an estimated $5.36M.
  • Point72 Asset Management first reported a position in BioAtla in Q3 2021 and held it in 3 quarters.
  • Point72 Asset Management's BioAtla position peaked at $5.89M in Q3 2022.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q1 2023.

Based on Point72 Asset Management's 13F filing for Q1 2023, filed 15 May 2023.